

In vivo validation of a novel class of pain medication



PRINCIPAL INVESTIGATORS:
Dr. Viola Seitz
Prof. Dr. Christoph Stein
Charité



SUMMARY

Although pain research has identified a plethora of targets, no truly innovative analgesics have reached the market in the past years, mostly due to low efficacy or severe side effects. This leaves a significant unmet medical need for novel, safe and effective compounds with reduced side effect burden and abuse liability.

The project seeks to complete external validation of *in vivo* data on NFEPP, a novel compound that has demonstrated potent pain relief without addiction potential in initial experiments. A patent has been filed and results were published in Science in 2017.

PROJECT GOALS

- External validation of preclinical *in vivo* studies
- Secure follow-on applied research funding

LONG-TERM GOALS

- Further develop under CMC and GMP conditions
- Test safety & toxicity of NFEPP
- Perform phase I/IIa clinical trials
- License to Pharma